LAVA Therapeutics Announces Progress and Stability

Lava Therapeutics Nv (LVTX) has released an update.

LAVA Therapeutics N.V. reports a robust end to 2023 with clinical advancements and a strong cash position to fund operations into 2026. Key highlights include progress in their Phase 1/2a study of LAVA-1207 for prostate cancer, a $7 million milestone payment from Pfizer for EGFRd2, and an anticipated IND submission for LAVA-1266 targeting acute myeloid leukemia. The company’s financial health is underlined by $95.6 million in cash reserves, with reduced expenses contributing to an extended financial runway.

For further insights into LVTX stock, check out TipRanks’ Stock Analysis page.